TriGemX Bio To Go Public Through Merger With TCGX Acquisition, Plans Nasdaq Listing Under TGEM; Upon Closing, Combined Company Expected to Receive ~$246M Of Gross Proceeds

TriGemX Bio is set to go public through a merger with TCGX Acquisition Corp., with plans to list on Nasdaq under the ticker symbol 'TGEM'. The transaction is expected to generate approximately $246 million in gross proceeds, which includes $86 million from TCGX's trust account and a $160 million private investment in public equity (PIPE) financing. The PIPE financing will involve shares sold at $10.00 each to various prominent healthcare investors.